1 results match your criteria: "Michael F Sorrell Center for Health Science Education[Affiliation]"
Taranabant, a novel cannabinoid type 1 receptor inverse agonist.
Curr Opin Investig Drugs
October 2008
University of Nebraska Medical Center, College of Medicine, Michael F Sorrell Center for Health Science Education, 15926 S St, Omaha, NE 68135, USA.
Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.
View Article and Find Full Text PDF